Despite these limitations, EGCG is able to
promote non-amyloidogenic processing of amyloid
precursor protein (APP) by upregulating α-secretase
preventing brain β-amyloid plaque formation, a
hallmark of Alzheimer’s disease and a common finding
in HIV infection. The use of this green tea polyphenol
provided promising preclinical results in mouse
models of both diseases. However, the translation into
clinical use highlighted the limitations related to poor
bioavailability and inefficient delivery to the central
nervous system (CNS).